Altered DNA methylation of the ABO gene is associated with differential plasma levels of von willebrand factor and E‐selectin
Transfusion · 2025-09 · 65 (9) · 1693-1706
DOI: 10.1111/trf.18342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 22.08.2025. Verfasst von Tianai Lou und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Trinity College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: ABO Blood-Group System, von Willebrand Factor, DNA Methylation, E-Selectin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, French government's Invest in the Future Programme, Science Foundation Ireland.
Abstract (Originalsprache)
Background
The ABO blood group system is associated with differential susceptibility to thrombotic vascular diseases. ABO is also known to be a strong trans ‐protein quantitative trait locus for plasma proteins involved in cell adhesion and hemostasis. Study Design and Method To further investigate these associations, we integrated epigenomic, genomic, and proteomic data from the Milieu Intérieur cohort. We used the rs8176719 SNP to classify donors as either type O or non‐O, and used linear models to compare levels of 229 plasma proteins in 400 donors, including age, sex, cytomegalovirus serostatus, and secretor status as covariates.
Results
We observed increased levels of soluble E‐selectin and decreased levels of von Willebrand Factor (vWF) in O donors compared with non‐O donors. By performing an epigenome‐wide association study, we identified 23 differentially methylated CpG sites between blood types, which were all located in the ABO gene. Notably, CpG sites in the ABO promoter region of type O donors were less methylated than those of the non‐O donors. Using mediation analysis, we found that these differences in DNA methylation partially explained the effects of blood group on differential E‐selectin and vWF plasma levels.
Discussion
We find differentially methylated CpG sites between blood types and provide new evidence that ABO blood group status affects circulating levels of specific proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Trinity College Dublin, Dublin, Ireland.
- Translational Immunology Unit, Institut Pasteur, Paris, France.
- Human Evolutionary Genetics Unit, Institut Pasteur, Université Paris Cité, Paris, France.
- Chair Human Genomics and Evolution, Collège de France, Paris, France.
- School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.
ORCID-Profile: Tianai Lou
Förderung
- Agence Nationale de la Recherche
- French government's Invest in the Future Programme
- Science Foundation Ireland
Zitieren
APA
Lou, T., Sugrue, J. A., Patin, E., Milieu Intérieur Consortium, Quintana-Murci, L., Duffy, D., & O'Farrelly, C. (2025). Altered DNA methylation of the ABO gene is associated with differential plasma levels of von willebrand factor and E‐selectin. Transfusion, 65(9), 1693-1706. https://doi.org/10.1111/trf.18342
Vancouver
Lou T, Sugrue JA, Patin E, Milieu Intérieur Consortium, Quintana-Murci L, Duffy D, et al. Altered DNA methylation of the ABO gene is associated with differential plasma levels of von willebrand factor and E‐selectin. Transfusion. 2025;65(9):1693-1706. doi:10.1111/trf.18342
BibTeX
@article{Lou2025,
author = {Lou, Tianai and Sugrue, Jamie A and Patin, Etienne and Milieu Intérieur Consortium, Milieu Intérieur Consortium and Quintana-Murci, Lluis and Duffy, Darragh and O'Farrelly, Cliona},
title = {Altered DNA methylation of the ABO gene is associated with differential plasma levels of von willebrand factor and E‐selectin},
journal = {Transfusion},
year = {2025},
volume = {65},
number = {9},
pages = {1693--1706},
doi = {10.1111/trf.18342}
}
EUVIMED